MRI Guided Focal Laser Ablation of Prostate Cancer
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Prostate Cancer
- Sponsor
- University Health Network, Toronto
- Enrollment
- 102
- Locations
- 1
- Primary Endpoint
- The proportion of study patients clinically free of clinically significant PCa (i.e. requires definitive treatment)
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
This clinical research study is designed to determine the ability of in bore MRI guided Focal Laser Ablation (MRgFLA) in patients with early stage carcinoma of prostate. The results will be evaluated by repeated MRI and prostate biopsy. Previous prospective development study demonstrated that FLA may be a viable option for men with low-intermediate risk prostate cancer. The vast majority of patients undergoing this treatment experienced minimal side effects with no peri-operative complications. Over 80% of patients treated with MRgFLA remain on AS and were able to avoid radical therapy at mean follow up duration of 3 years.
Detailed Description
Study Objectives are to evaluate the proportion of patients with low-intermediate risk prostate cancer undergoing focal laser ablation (MRgFLA) prostate treatment who will be free of clinically significant Prostate Cancer (PCa), when using a \> 5mm margins around the MR visible tumor in defining the ablation contour. The rationale of the study is to show that MRgFLA is a safe procedure that can significantly postpone or eliminate the need for patients with Low-Intermediate Risk prostate cancer to undergo a definitive treatment (i.e., Radical Prostatectomy or Radiation therapy) for their disease. Study population: patients with Low-Intermediate Risk Prostate Cancer who are willing to take part in the study and meet study eligibility criteria. Primary Study Objective is to show that MRgFLA can significantly reduce the need for definitive treatment (e.g., Radical Prostatectomy, or Radiation therapy) and is a safe procedure for patients with Low-Intermediate Risk Prostate Cancer defined in the current protocol as 1) Gleason score 6 and 7 (=3+4 or 4+3; No Grade 5 pattern), and 2) T1-T2, N0, M0.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Men 40-80 years of age
- •Histologically proven low-intermediate risk prostate carcinoma; (Gleason score ≤ 7, primary grade ≤ 4;)
- •Prostate cancer clinical stage T1c and T2
- •MR site suspicious for cancer or cancer mapped to one lobe of the prostate using the 3D hybrid TRUS device
- •Size of MR visible tumor \<20mm
- •Suspicious site on Prostate MRI must coincide with sector positive for cancer on biopsy
- •Prostate specific antigen (PSA) level \<15 ng/mL
- •IPSS, ICIQ-UI-SF, IIEF complete prior to procedure
- •Life expectancy of greater than 10 years, based on co-morbidity not related to prostate cancer.
Exclusion Criteria
- •Medically unfit for focal therapy of the prostate
- •Patients who are unwilling or unable to give informed consent;
- •Patients who have received androgen suppression therapy
- •Patients who have received or are receiving chemotherapy for prostate carcinoma;
- •Patients previously treated with surgery to the prostate (traditional, endoscopic or minimally invasive including HIFU, TUNA, RITA, microwave, cryotherapy or any curative treatment
- •Patients who have undergone radiation therapy for prostate cancer or to the pelvis
- •Any condition, or history of illness or surgery that, in the opinion of the Investigator, might confound the results of the study or pose additional risks to the patient (e.g. significant cardiovascular conditions or allergies);
- •Patients with a history of noncompliance with medical therapy and/or medical recommendations;
- •Patients who are unwilling or unable to complete the patient self-assessment questionnaires;
- •Chronic or acute prostatitis, neurogenic bladder, urinary tract infection, sphincter abnormalities, or any other symptom that prevents normal micturition.
Outcomes
Primary Outcomes
The proportion of study patients clinically free of clinically significant PCa (i.e. requires definitive treatment)
Time Frame: 24 months after treatment completion
Clinically significant PCa will be defined as recurrent/residual Gleason 3+4 or higher, and/or high-volume Gleason 6 disease found at 24-month biopsy.
Secondary Outcomes
- Treatment effect on patients' Quality of Life (QoL), the following validated self-reported urogenital functioning assessment instruments will be used before and following treatment at pre-specified interval(Baseline before treatment, 30 days, 6 months, 12 months and at 24 months following treatment)